Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Trial sites expanded: 4 → 7 locations GlaxoSmithKlinePhase 3 NCT07782957
  2. Minor: Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations Hoffmann-La RochePhase 3 NCT07843472
  3. Minor: Fixed Doses of SEP-363856 · Generalized Anxiety Disorder Trial sites expanded: 17 → 27 locations Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT07759128
  4. Minor: Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment · Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Trial sites expanded: 34 → 69 locations GenmabPhase 3 NCT07225270
  5. Minor: Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Trial sites expanded: 7 → 12 locations Hoffmann-La RochePhase 2 NCT07781657
  6. Minor: NX-5948 · CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Trial sites expanded: 43 → 47 locations Nurix Therapeutics, Inc.Phase 2 NCT07221500
  7. Minor: QCZ484 in Hypertensive Patients Trial sites expanded: 25 → 46 locations Novartis PharmaceuticalsPhase 2 NCT07543120
  8. Minor: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations argenxPhase 2 NCT07673627
  9. Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations Sarepta Therapeutics, Inc.Phase 1 NCT07536061
  10. Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations Merck Sharp & Dohme LLCNot specified NCT02653118
  11. Minor: Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab · Moderate to Severe HS Within the Italian Population Trial sites expanded: 16 → 22 locations Novartis PharmaceuticalsNot specified NCT07543419
  12. Minor: NIS Evaluating Various Injectable and Oral Treatments · Relapsing Multiple Sclerosis Trial sites expanded: 141 → 146 locations Novartis PharmaceuticalsNot specified NCT05344469
  13. Minor: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia Trial sites expanded: 42 → 49 locations Novartis PharmaceuticalsNot specified NCT06930859
  14. Minor: Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery · Early-stage, Operable, Non-small Cell Lung Cancer Trial sites expanded: 42 → 45 locations ETOP IBCSG Partners FoundationPhase 3 NCT06284317
  15. Minor: Biomarker Targeted Stimulation for Epileptiform Events Trial sites expanded: 0 → 4 locations Cadence NeuroscienceNot applicable NCT06424977
  16. Minor: VitaSmart HOPE System: Bridge to HOPE Registry Trial sites expanded: 1 → 9 locations Bridge to Life Ltd.Not specified NCT07578441
  17. Minor: Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit Enrollment increased: 954 → 1054 participants Centre Hospitalier Régional Metz-ThionvilleNot applicable NCT05475574
  18. Minor: Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients Enrollment increased: 300 → 400 participants University of UtahNot specified NCT06875700
  19. Minor: Canadian Critical Care Comparative Effectiveness Platform Trial sites expanded: 11 → 14 locations Université de SherbrookePhase 3 NCT06605144
  20. Minor: Inclisiran Versus Placebo · Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Trial sites expanded: 149 → 153 locations Duke UniversityPhase 4 NCT06909565
  21. Minor: Monotherapy With P2Y12 Inhibitors · Atrial fIbrillation Undergoing Drug-eluting Stent Implantation Trial sites expanded: 15 → 18 locations Insel Gruppe AG, University Hospital BernPhase 4 NCT05955365
  22. Minor: European Disease Registry on Retinopathy of Prematurity (ROP) Trial sites expanded: 59 → 79 locations University Medicine GreifswaldNot specified NCT04939571
  23. Minor: Cardiogenic Shock Working Group Registry Trial sites expanded: 16 → 22 locations Tufts Medical CenterNot specified NCT04682483
  24. Minor: Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets · Overweight or Obesity Interventions modified Hangzhou Sciwind Biosciences Co., Ltd.Phase 1/2 NCT07243171
  25. Minor: Effects and Safety of RO7568282 in Early Parkinson's Disease Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026 Hoffmann-La RochePhase 2 NCT07781644